Nurix reports FY2022 net loss $180.4M, cash $373M; NX-2127 shows clinical benefit in CLL

Nurix Therapeutics, Inc.

Net loss for FY ended Nov 30, 2022: $180.4M ($3.71/shr) vs $117.2M ($2.73/shr) in FY2021; R&D expense $184.5M.
Cash and marketable securities at $373.0M on Nov 30, 2022, down from $432.9M at Nov 30, 2021; collaboration revenue $38.6M.
NX-2127 BTK degrader achieved clinical responses in heavily pretreated CLL patients with BTK inhibitor resistance mutations.
Initial PK/PD data for NX-5948 showed rapid, sustained BTK degradation; FDA clearance for US trial expansion received Dec 2022.
Nurix expects to present additional clinical data for NX-2127, NX-5948, and NX-1607 in 2H 2023; partnered 10 discovery programs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nurix Therapeutics, Inc. reported financial results for the fourth quarter and fiscal year ended November 30, 2022.

Period: the fourth quarter and fiscal year ended November 30, 2022
Result: reported results

Exact text from the filing

On February 9, 2023, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended November 30, 2022.

View on SEC.gov

Browse all earnings releases →

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001549595-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.